Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NTLA · as of Sep 30, 2025
Ownership Breakdown
310
Institutional Holders
▲ 9 vs Q2
$1.80B
Total Inst. Value
▲ $865.45M vs Q2
112.21M
Shares Outstanding
freeFloat 94.68%
104.20M
13F Shares Held
▲ 4.66M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NTLA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ARK INVESTMENT MANAGEMENT LLC in vitro & in vivo diagnostic substances | 11.92M | 10.82% | 10.82% | $205.84B | Nov 12, 2025 | ▼ 1.10M |
VANGUARD GROUP INC in vitro & in vivo diagnostic substances | 11.04M | 10.02% | 10.02% | $190.74B | Nov 7, 2025 | ▲ 192.7K |
BLACKROCK, INC. in vitro & in vivo diagnostic substances | 9.28M | 8.42% | 8.42% | $160.19B | Nov 12, 2025 | ▼ 751.4K |
MORGAN STANLEY in vitro & in vivo diagnostic substances | 6.02M | 5.81% | 5.81% | $104.01B | May 27, 2026 | ▲ 1.91M |
CONTRARIUS GROUP HOLDINGS LTD in vitro & in vivo diagnostic substances | 5.89M | 5.35% | 5.35% | $101.72B | Nov 12, 2025 | ▲ 4.34M |
STATE STREET CORP in vitro & in vivo diagnostic substances | 4.97M | 4.51% | 4.51% | $85.85B | Nov 14, 2025 | ▲ 931.6K |
GOLDMAN SACHS GROUP INC in vitro & in vivo diagnostic substances | 4.28M | 3.88% | 3.88% | $73.89B | Nov 14, 2025 | ▲ 2.23M |
REGENERON PHARMACEUTICALS, INC. in vitro & in vivo diagnostic substances | 3.70M | 3.36% | 3.36% | $63.95B | Nov 7, 2025 | — held |
BAKER BROS. ADVISORS LP in vitro & in vivo diagnostic substances | 2.75M | 2.49% | 2.49% | $47.44B | Nov 14, 2025 | ▲ 71.0K |
GEODE CAPITAL MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 2.59M | 2.35% | 2.35% | $44.71B | Nov 12, 2025 | ▼ 17.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+13.90M shares5
New Positions
first time holders18
Decreased
−4.70M shares0
Sold Out
fully exitedNet shares change (top 50)
+9.21M
+13.90M / −4.70M
Net new holders
+13
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NTLA insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
14
Buy transactions
9
Sell transactions
1.56
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
LEONARD JOHN M President and CEO | Mar 1, 2026 | Award | 156,400 | — | — | 1.17M | Form 4 ↗ |
LEONARD JOHN M President and CEO | Mar 1, 2026 | Award | 225,400 | $13.78 | $3.11M | 225.4K | Form 4 ↗ |
BASTA JAMES EVP, General Counsel | Mar 1, 2026 | Award | 46,080 | — | — | 158.0K | Form 4 ↗ |
BASTA JAMES EVP, General Counsel | Mar 2, 2026 | Sale | 1,211 | $13.78 | $16.7K | 156.8K | Form 4 ↗ |
BASTA JAMES EVP, General Counsel | Mar 1, 2026 | Award | 65,829 | $13.78 | $907.1K | 65.8K | Form 4 ↗ |
Lebwohl David EVP, Chief Medical Officer | Mar 1, 2026 | Award | 9,943 | — | — | 131.2K | Form 4 ↗ |
Lebwohl David EVP, Chief Medical Officer | Mar 1, 2026 | Award | 14,204 | $13.78 | $195.7K | 14.2K | Form 4 ↗ |
Dulac Edward J III EVP, Chief Financial Officer | Mar 1, 2026 | Award | 61,280 | — | — | 161.0K | Form 4 ↗ |
Dulac Edward J III EVP, Chief Financial Officer | Mar 1, 2026 | Award | 87,543 | $13.78 | $1.21M | 87.5K | Form 4 ↗ |
Schultes Birgit C EVP, Chief Scientific Officer | Mar 1, 2026 | Award | 39,200 | — | — | 137.7K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Intellia Therapeutics, Inc. (NTLA) is primarily owned by institutional investors, who hold approximately 92.9% of total shares outstanding. Company insiders own approximately 5.32%, while retail and public investors account for the remaining 1.82%.
The largest institutional shareholder of Intellia Therapeutics, Inc. is ARK INVESTMENT MANAGEMENT LLC, holding approximately 11.92 million shares — equal to 10.82% of outstanding shares — as of September 30, 2025.
A total of 310 institutional investors currently hold NTLA stock, with a combined institutional value of approximately $1.80 billion as of the most recent 13F filing period.
Frequently asked questions
NTLA ownershipIntellia Therapeutics, Inc. (NTLA) is primarily owned by institutional investors, who hold approximately 92.9% of shares. The largest shareholder is ARK INVESTMENT MANAGEMENT LLC with a 10.82% stake. Company insiders hold 5.32%. Data sourced from SEC Form 13F as of September 30, 2025.